Literature DB >> 31891655

Assessment of health-related quality of life among adults hospitalized with sickle cell disease vaso-occlusive crisis.

Kimberly S Esham1,2,3,4, Angie Mae Rodday1,2,4, Hedy P Smith2,3,4, Farzad Noubary1,2,4, Ruth Ann Weidner1, Rachel J Buchsbaum2,3,4, Susan K Parsons1,2,3,4,5.   

Abstract

Sickle cell disease (SCD) is characterized by painful vaso-occlusive crises (VOCs). Self-reported pain intensity is often assessed with the Numeric Rating Scale (NRS), whereas newer patient-reported outcome measures (PROMs) assess multidimensional pain in SCD. We describe pain experiences among hospitalized adults with VOCs, using 2 PROMs: the Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health and the Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me). Adults with SCD hospitalized with VOCs at 2 academic centers in Boston, Massachusetts, from April 2016 to October 2017 were eligible. Participants completed the NRS and PROMs at admission and 7 days postdischarge. PROM scores were described and compared with population norms. Length of stay (LOS) and 30-day readmission rates were assessed. Forty-two (96%) of 44 eligible patients consented and completed admission assessments. Mean age was 30.2 years (standard deviation, 9.1), 60% were women, 76% were non-Hispanic black, and 64% had hemoglobin SS. Twenty-seven participants (64%) completed postdischarge assessments. Sixty percent had ≥4 VOCs in the last year. Nearly all PROMIS Global Health and ASCQ-Me scores were worse than population norms. NRS and PROMIS Global Physical Health scores improved after discharge, the latter driven principally by improvements in pain. Overall median LOS was 7 days, and 30-day readmission rate was 40.5%. Administration of PROMs among adults with SCD hospitalized for VOCs is feasible and demonstrates participants experienced recurrent, prolonged, and severe VOCs. PROMIS Global and ASCQ-Me scores indicated substantial suffering, and the striking 30-day readmission rate highlights the vulnerability of these patients.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2020        PMID: 31891655      PMCID: PMC6960476          DOI: 10.1182/bloodadvances.2019000128

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  41 in total

1.  Interviewer- versus self-administration of PROMIS® measures for adults with traumatic injury.

Authors:  Pamela A Kisala; Aaron J Boulton; Matthew L Cohen; Mary D Slavin; Alan M Jette; Susan Charlifue; Robin Hanks; M J Mulcahey; David Cella; David S Tulsky
Journal:  Health Psychol       Date:  2019-05       Impact factor: 4.267

2.  Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment.

Authors:  Ethan Basch; Allison M Deal; Amylou C Dueck; Howard I Scher; Mark G Kris; Clifford Hudis; Deborah Schrag
Journal:  JAMA       Date:  2017-07-11       Impact factor: 56.272

3.  United States Population-Based Estimates of Patient-Reported Outcomes Measurement Information System Symptom and Functional Status Reference Values for Individuals With Cancer.

Authors:  Roxanne E Jensen; Arnold L Potosky; Carol M Moinpour; Tania Lobo; David Cella; Elizabeth A Hahn; David Thissen; Ashley Wilder Smith; Jaeil Ahn; George Luta; Bryce B Reeve
Journal:  J Clin Oncol       Date:  2017-04-20       Impact factor: 44.544

4.  Predictors of health-related quality of life over time among adolescents and young adults with sickle cell disease.

Authors:  Jamie L Jackson; Kathleen L Lemanek; Emily Clough-Paabo; Melissa Rhodes
Journal:  J Clin Psychol Med Settings       Date:  2014-12

Review 5.  Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice?

Authors:  Fabio Efficace; Gianluca Gaidano; Francesco Lo-Coco
Journal:  Blood       Date:  2017-07-10       Impact factor: 22.113

6.  Health-related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium.

Authors:  Carlton Dampier; Petra LeBeau; Seungshin Rhee; Susan Lieff; Karen Kesler; Samir Ballas; Zora Rogers; Winfred Wang
Journal:  Am J Hematol       Date:  2011-02       Impact factor: 10.047

7.  Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance.

Authors:  Samir K Ballas; Margaret Lusardi
Journal:  Am J Hematol       Date:  2005-05       Impact factor: 10.047

8.  Risk factors for hospital readmission within 30 days: a new quality measure for children with sickle cell disease.

Authors:  Melissa J Frei-Jones; Joshua J Field; Michael R DeBaun
Journal:  Pediatr Blood Cancer       Date:  2009-04       Impact factor: 3.167

9.  Making Patients and Doctors Happier - The Potential of Patient-Reported Outcomes.

Authors:  Lisa S Rotenstein; Robert S Huckman; Neil W Wagle
Journal:  N Engl J Med       Date:  2017-10-05       Impact factor: 91.245

10.  Sensitivity of alternative measures of functioning and wellbeing for adults with sickle cell disease: comparison of PROMIS® to ASCQ-Me℠.

Authors:  San Keller; Manshu Yang; Marsha J Treadwell; Kathryn L Hassell
Journal:  Health Qual Life Outcomes       Date:  2017-06-02       Impact factor: 3.186

View more
  8 in total

Review 1.  What is the future of patient-reported outcomes in sickle-cell disease?

Authors:  Sharon A Singh; Nitya Bakshi; Prashant Mahajan; Claudia R Morris
Journal:  Expert Rev Hematol       Date:  2020-10-15       Impact factor: 2.929

2.  Health State Utilities for Sickle Cell Disease: A Catalog Prepared From a Systematic Review.

Authors:  Boshen Jiao; Anirban Basu; Scott Ramsey; Joshua Roth; M A Bender; Dalyna Quach; Beth Devine
Journal:  Value Health       Date:  2021-09-04       Impact factor: 5.725

Review 3.  Microfluidic methods to advance mechanistic understanding and translational research in sickle cell disease.

Authors:  Melissa Azul; Eudorah F Vital; Wilbur A Lam; David K Wood; Joan D Beckman
Journal:  Transl Res       Date:  2022-03-27       Impact factor: 10.171

4.  Correction of murine sickle cell disease by allogeneic haematopoietic cell transplantation with anti-3rd party veto cells.

Authors:  Aloukick Kumar Singh; Elias Schetzen; Sandeep Kumar Yadav; Esther Bachar Lustig; Wei-Hsin Liu; Raj Kumar Yadav; Robert Peter Gale; Kathryn McGinnis; Yair Reisner
Journal:  Bone Marrow Transplant       Date:  2021-03-03       Impact factor: 5.174

5.  Clusters of pain trajectories among patients with sickle cell disease hospitalized for vaso-occlusive crisis: a data-driven approach.

Authors:  Angie Mae Rodday; Kimberly S Esham; Nicole Savidge; Susan K Parsons
Journal:  EJHaem       Date:  2020-10-22

6.  An evaluation of patient-reported outcomes in sickle cell disease within a conceptual model.

Authors:  Marsha J Treadwell; Swapandeep Mushiana; Sherif M Badawy; Liliana Preiss; Allison A King; Barbara Kroner; Yumei Chen; Jeffrey Glassberg; Victor Gordeuk; Nirmish Shah; Angela Snyder; Theodore Wun
Journal:  Qual Life Res       Date:  2022-04-21       Impact factor: 3.440

7.  Health-related quality of life in hemoglobinopathies: A systematic review from a global perspective.

Authors:  Francesca Rodigari; Giorgia Brugnera; Raffaella Colombatti
Journal:  Front Pediatr       Date:  2022-08-25       Impact factor: 3.569

8.  Patterns of healthcare utilization among patients with sickle cell disease hospitalized with pain crises.

Authors:  Angie Mae Rodday; Kimberly S Esham; Nicole Savidge; Susan K Parsons
Journal:  EJHaem       Date:  2020-10-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.